Nuvectis Q2 2024 net loss narrows to $4.4M; progressing NXP800 and NXP900 trials

Nuvectis Pharma, Inc.

2024-Q2 EPS reported -$0.51

Cash $18.1M at June 30, 2024, down $1.4M from March 31, 2024; net loss $4.4M vs $5.8M YoY.
R&D spend $2.9M (-33% YoY); G&A $1.7M (+13%); interest income $0.2M.
NXP800 Phase 1b ovarian cancer trial enrolling at ~15 US/UK sites; update due fall 2024.
NXP800 investigator-sponsored cholangiocarcinoma trial recruiting; update expected by end of 2024.
NXP900 dose escalation: 3 cohorts complete, no DLTs; planning combo with EGFR/ALK inhibitors in NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.